K. Lauritsen

6.7k total citations · 1 hit paper
108 papers, 5.3k citations indexed

About

K. Lauritsen is a scholar working on Surgery, Gastroenterology and Epidemiology. According to data from OpenAlex, K. Lauritsen has authored 108 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Surgery, 50 papers in Gastroenterology and 24 papers in Epidemiology. Recurrent topics in K. Lauritsen's work include Helicobacter pylori-related gastroenterology studies (59 papers), Gastroesophageal reflux and treatments (40 papers) and Eosinophilic Esophagitis (26 papers). K. Lauritsen is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (59 papers), Gastroesophageal reflux and treatments (40 papers) and Eosinophilic Esophagitis (26 papers). K. Lauritsen collaborates with scholars based in Denmark, Sweden and Australia. K. Lauritsen's co-authors include J Rask-Madsen, Klaus Bukhave, Nicholas J. Talley, L. Laursen, Laurits S. Laursen, Troels Havelund, Ola Junghard, Tore Lind, A. Mark Fendrick and E. Bolling‐Sternevald and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

K. Lauritsen

102 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An evidence-based appraisal of reflux disease management — the Genval Workshop Report

1998 681 citations John Dent, Johan G. Brun et al. Gut profile →

Peers

Countries citing papers authored by K. Lauritsen

Since Specialization

Citations

This map shows the geographic impact of K. Lauritsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Lauritsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Lauritsen more than expected).

Fields of papers citing papers by K. Lauritsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Lauritsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Lauritsen. The network helps show where K. Lauritsen may publish in the future.

Co-authorship network of co-authors of K. Lauritsen

This figure shows the co-authorship network connecting the top 25 collaborators of K. Lauritsen. A scholar is included among the top collaborators of K. Lauritsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Lauritsen. K. Lauritsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1) 2004 ·Gastroenterology ·Paul Rutgeerts, (unknown), Antoine Cortot, G. D’Haens, (unknown), Xavier Hébuterne, K. Lauritsen, Robert Löfberg, Thomas Ochsenkühn, Stefan Schreiber, D Vetter, Karel Geboes	9
2	Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn's disease: results from ENACT-1 2004 ·Gastroenterology ·Karel Geboes, (unknown), Antoine Cortot, G. D’Haens, (unknown), Xavier Hébuterne, K. Lauritsen, Robert Löfberg, Thomas Ochsenkühn, Stefan Schreiber, D Vetter, Paul Rutgeerts	3
3	Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture 2004 ·Controlled Clinical Trials ·K. Lauritsen, Alessio Degl’ Innocenti, (unknown), (unknown), (unknown), (unknown), Ingela Wiklund	60
4	The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole 2004 ·Alimentary Pharmacology & Therapeutics ·David Armstrong, Nicholas J. Talley, K. Lauritsen, Bjørn Moum, Tore Lind, (unknown), (unknown), (unknown), Marc‐André Bigard, Joachim Mössner, Ola Junghard	70
5	Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study☆, ☆☆ 1999 ·Gastroenterology ·(unknown), Jens Lauritsen, Jesper Hallas, (unknown), Karen A. Krogfelt, K. Lauritsen	126
6	Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up 1999 ·BMJ ·Nicholas J. Talley, J. Janssens, K. Lauritsen, I Rácz, E. Bolling‐Sternevald	227
7	An evidence-based appraisal of reflux disease management — the Genval Workshop Report breakdown → 1998 ·Gut ·John Dent, Johan G. Brun, A. Mark Fendrick, M. Brian Fennerty, (unknown), (unknown), K. Lauritsen, James C. Reynolds, (unknown), Nicholas J. Talley	681
8	5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. 1992 ·PubMed ·J Rask-Madsen, Klaus Bukhave, L. Laursen, K. Lauritsen	53
9	Final Report on a Placebo-Controlled, Double-Blind, Randomized, Multicentre Trial of Cyclosporin Treatment in Active Chronic Crohn's Disease 1991 ·Scandinavian Journal of Gastroenterology ·Jørn Brynskov, L Freund, Sten Nørby Rasmussen, K. Lauritsen, Ove B. Schaffalitzky de Muckadell, C. N. Williams, A. S. Macdonald, (unknown), Francisco Fidencio Cons Molina, Mauro Campanini, Paola Bianchi, T Ranzi, F. Quarto di Palo, A Malchow-Møller, Ole Østergaard Thomsen, Ulrik Tage‐Jensen, V. Binder, P Riis	68
10	Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. 1990 ·Gut ·L. Laursen, Morten Gersel Stokholm, Klaus Bukhave, J Rask-Madsen, K. Lauritsen	148
11	Selective 5-lipoxygenase inhibition in ulcerative colitis 1990 ·The Lancet ·L. Laursen, K. Lauritsen, J. Næsdal, J Rask-Madsen, Klaus Bukhave	101
12	Omeprazole in the Treatment of Prepyloric Ulcer: Review of the Results of the Danish Omeprazole Study Group 1989 ·Scandinavian Journal of Gastroenterology ·K. Lauritsen	1
13	Low‐dose cyclosporin for Crohn's disease: implications for clinical trials 1989 ·Alimentary Pharmacology & Therapeutics ·Jørn Brynskov, V. Binder, P Riis, K. Lauritsen, Ove B. Schaffalitzky de Muckadell, L Freund, Jan Fallingborg, Sten Nørby Rasmussen, Peter Matzen, E Krag, Ulrik Tage‐Jensen, (unknown)	16
14	Inflammatory intermediaries in inflammatory bowel disease 1989 ·International Journal of Colorectal Disease ·K. Lauritsen, L. Laursen, Klaus Bukhave, J Rask-Madsen	39
15	Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. 1988 ·Gut ·K. Lauritsen, L. Laursen, Klaus Bukhave, J Rask-Madsen	36
16	In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. 1987 ·Gut ·K. Lauritsen, L. Laursen, Klaus Bukhave, J Rask-Madsen	75
17	Effects of Cisapride on Gastroparesis in Patients with Insulin‐dependent Diabetes Mellitus 1987 ·Acta Medica Scandinavica ·Troels Havelund, (unknown), Ole Eshøj, Mogens Lytken Larsen, K. Lauritsen	42
18	Enprostil and ranitidine in duodenal ulcer healing: double blind comparative trial. 1986 ·BMJ ·K. Lauritsen, L. Laursen, Troels Havelund, Peter Bytzer, Lars Bo Svendsen, J Rask-Madsen	39
19	Arbaprostil in bleeding peptic ulcer 1985 ·BMJ ·K. Lauritsen, L. Laursen, Troels Havelund, Peter Bytzer, J Rask-Madsen	1
20	Controlled trial of arbaprostil in bleeding peptic ulcer. 1985 ·BMJ ·K. Lauritsen, L. Laursen, Troels Havelund, Peter Bytzer, J Rask-Madsen	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact